Literature DB >> 25686575

Use of quetiapine in children and adolescents.

Gabriele Masi1, Annarita Milone, Stefania Veltri, Raffaella Iuliano, Chiara Pfanner, Simone Pisano.   

Abstract

The atypical antipsychotic quetiapine has been used in different psychotic and non-psychotic disorders in children and adolescents in randomized clinical trials, open-label studies and chart reviews. Most of these studies suggest that quetiapine may be a promising agent with a potential for use in young patients. The aim of this paper is to critically review available literature on quetiapine in the treatment of children and adolescents with a variety of psychiatric disorders, including psychotic disorders, bipolar disorders (manic and depressive episodes), conduct disorder, autism spectrum disorder, Tourette's syndrome and personality disorders. Furthermore, we report on possible neurochemical pathways involved during treatment with quetiapine, and discuss some issues that are clinically relevant in daily practice, such as titration strategies, safety and tolerability, and monitoring possible side effects. Controlled studies support the short-term efficacy for treating psychosis, mania, and aggression within certain diagnostic categories. However, although quetiapine seems well tolerated in various pediatric populations during acute and intermediate treatments, and hyper-prolactinemia and extra-pyramidal side effects are consistently low among studies, weight gain and alterations in lipid profile need to be closely monitored. Furthermore, the distal benefit/risk ratio during long-term treatment remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25686575     DOI: 10.1007/s40272-015-0119-3

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  63 in total

1.  A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder.

Authors:  Gagan Joshi; Carter Petty; Janet Wozniak; Stephen V Faraone; Robert Doyle; Anna Georgiopoulos; Paul Hammerness; Sarah Walls; Breanna Glaeser; Kristin Brethel; Dayna Yorks; Joseph Biederman
Journal:  J Affect Disord       Date:  2011-10-28       Impact factor: 4.839

2.  Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.

Authors:  Trevor N Johnson; Diansong Zhou; Khanh H Bui
Journal:  Biopharm Drug Dispos       Date:  2014-08-06       Impact factor: 1.627

3.  Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.

Authors:  Celso Arango; Miriam Giráldez; Jessica Merchán-Naranjo; Inmaculada Baeza; Josefina Castro-Fornieles; Jose-Angel Alda; Carmen Martínez-Cantarero; Carmen Moreno; Pilar de Andrés; Cristina Cuerda; Elena de la Serna; Christoph U Correll; David Fraguas; Mara Parellada
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-09-02       Impact factor: 8.829

4.  The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents.

Authors:  Josip Podobnik; Iris Foller Podobnik; Neda Grgic; Darko Marcinko; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2011-12-16       Impact factor: 4.530

5.  Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.

Authors:  Donald L Gilbert; J Robert Batterson; Gopalan Sethuraman; Floyd R Sallee
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-02       Impact factor: 8.829

6.  A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents.

Authors:  Nick C Patel; Jennifer S Kistler; Elizabeth B James; M Lynn Crismon
Journal:  Pharmacotherapy       Date:  2004-07       Impact factor: 4.705

7.  Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.

Authors:  William G Kronenberger; Ann L Giauque; Deborah E Lafata; Bradley N Bohnstedt; Laura E Maxey; David W Dunn
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

8.  Quetiapine treatment of children and adolescents with Tourette's disorder.

Authors:  Nahit Motavali Mukaddes; Osman Abali
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

9.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode.

Authors:  Celso Arango; Olalla Robles; Mara Parellada; David Fraguas; Ana Ruiz-Sancho; Oscar Medina; Arantzazu Zabala; Igor Bombín; Dolores Moreno
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-05       Impact factor: 4.785

10.  Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.

Authors:  Anne Katrine Pagsberg; Pia Jeppesen; Dea Gowers Klauber; Karsten Gjessing Jensen; Ditte Rudå; Marie Stentebjerg-Olesen; Peter Jantzen; Simone Rasmussen; Eva Ann-Sofie Saldeen; Maj-Britt Glenn Lauritsen; Niels Bilenberg; Anne Dorte Stenstrøm; Jesper Pedersen; Louise Nyvang; Sarah Madsen; Marlene B Lauritsen; Ditte Lammers Vernal; Per Hove Thomsen; Jakob Paludan; Thomas M Werge; Kristian Winge; Klaus Juul; Christian Gluud; Maria Skoog; Jørn Wetterslev; Jens Richardt M Jepsen; Christoph U Correll; Anders Fink-Jensen; Birgitte Fagerlund
Journal:  BMC Psychiatry       Date:  2014-07-11       Impact factor: 3.630

View more
  8 in total

1.  Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more.

Authors:  Ahmed Naguy
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

2.  Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.

Authors:  Simone Pisano; Giangennaro Coppola; Gennaro Catone; Marco Carotenuto; Raffaella Iuliano; Vittoria D'Esposito; Serena Cabaro; Emanuele Miraglia Del Giudice; Carmela Bravaccio; Pietro Formisano
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

3.  Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.

Authors:  Richard H Parrish; Lisa D Ashworth; Raimar Löbenberg; Sandra Benavides; Jeffrey J Cies; Robert B MacArthur
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

4.  Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project.

Authors:  Elaine Stephanie Chow; Azadeh Zangeneh-Kazemi; Olabode Akintan; Elizabeth Chow-Tung; Alan Eppel; Khrista Boylan
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2017-07-01

5.  Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder.

Authors:  Jianbo Lai; Qiaoqiao Lu; Tingting Huang; Shaohua Hu; Yi Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-19       Impact factor: 2.570

6.  Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey.

Authors:  Devon M Coleman; James B Adams; Amy L Anderson; Richard E Frye
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-02-06       Impact factor: 2.576

Review 7.  Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.

Authors:  Simone Pisano; Gennaro Catone; Stefania Veltri; Valentina Lanzara; Marco Pozzi; Emilio Clementi; Raffaella Iuliano; Maria Pia Riccio; Sonia Radice; Massimo Molteni; Annalisa Capuano; Antonella Gritti; Giangennaro Coppola; Annarita Milone; Carmela Bravaccio; Gabriele Masi
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

Review 8.  Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.

Authors:  Christian Popow; Susanne Ohmann; Paul Plener
Journal:  Neuropsychiatr       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.